B+
Bull case
20%
Probability
Target price
$1.65
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
SNDL
SNDLCNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$1.15
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.75
Analysis reference price unavailable
Analysis 2026-08-07 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-08-07
Recent news sentiment (30D)
-0.5
Mixed
Company
-
Unavailable
Macro
-
Unavailable
Pulse
-
Unavailable
Weekly research (10D)
-
Unavailable
Sentiment proxy
+42.9
Score
AI commentary
The official Q2 release is fundamentally mixed-to-negative: weak revenue and margins outweighed liquidity, buybacks, and the Parallel milestone [#PR-SNDL-Q2-2026-07-28]. Available market coverage reported a negative post-print reaction, while analyst revisions and target changes are unavailable. Social, options, and insider signals are also unavailable, and the peer set is limited to a small number of cannabis operating read-throughs, so this remains a low-conviction monitoring view rather than a directional bullish thesis.
RankAlpha Sentiment Codex - 2026-08-07
Open full AI memoEvidence flagged
Coverage is limited for this name, so the memo relies on a thinner evidence base.; small-cap biotech peer set is too weak or includes unrelated comparators for a standard-conviction report
Impact
tentative
Confidence
-
AI events
2026-07-28eventQ2 2026 earnings reset the near-term thesisMedium impact
Official results showed revenue down 3.7% year over year, gross margin down 3.7 percentage points to 23.9%, and a C$7.8 million operating loss versus prior-year operating income. Management cited market softness and Jeeter production ramp-up inefficiencies [#PR-SNDL-Q2-2026-07-28].
2026-11-05catalystMargin and demand repair remain the immediate testHigh impact
Liquor same-store sales declined 6.2%, Cannabis Operations gross margin fell to 1.8%, and first-half adjusted operating loss widened materially. Management expects stronger second-half performance, but execution evidence is still limited [#PR-SNDL-Q2-2026-07-28].
2026-12-31catalystCapital strength and buybacks provide valuation supportHigh impact
SNDL reported C$183.2 million of unrestricted cash, no debt, 11.7 million shares repurchased in Q2, and a target of positive free cash flow for the full year. Cash generation and continued repurchases remain unproven after negative Q2 free cash flow [#PR-SNDL-Q2-2026-07-28].
Recommendation
N/A
No formal recommendation provided.
As of 2026-08-07 • Updated nightlySource: Internal modelMethodology